Sarepta’s Exondys Successor Bounces Back From Clinical Hold But All Eyes On Gene Therapy
The firm’s exon-skipping Duchenne muscular dystrophy asset will resume clinical study in the US following the lifting of a clinical hold but observers seem more invested in the fate of its gene therapy candidate for the condition.
You may also be interested in...
Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.
More data from Sarepta’s mid-stage studies help bolster confidence in the gene therapy but will the US FDA call in the drug for an early appraisal or await Phase III data next year?
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.